Scribe Therapeutics’ early-stage IPO surges 43% as epigenetic cholesterol drug enters clinic

Scribe Therapeutics filed for an IPO while its lead epigenetic therapy moves into early clinical testing, a rare combination in a market that prefers later-stage, de-risked offerings.

The company raised an upsized $150 million and its shares jumped 43 percent from the $21.50 opening price to close at $31.05, outperforming the biotech index XBI, which rose about 12 percent over the same period.

Scribe’s lead asset, STX‑1150, is a single‑dose epigenetic silencer intended to lower low‑density lipoprotein cholesterol and reduce the need for daily medication, while avoiding permanent gene edits.

Analysts note that the company’s fate will hinge on data expected early next year, and that investors are watching to see if an early‑stage, high‑risk play can succeed in a climate that usually rewards later‑stage assets.